Have a feature idea you'd love to see implemented?
Let us know!
PIRS Pieris Pharmaceuticals Inc
Price (delayed)
$15.934
Market cap
$21.04M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$12.1
Enterprise value
$1.67M
Pieris Pharmaceuticals Inc.is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Its pipeline includes inhalable Anticalin
Highlights
Pieris Pharmaceuticals's quick ratio has soared by 199% YoY and by 42% from the previous quarter
The debt has shrunk by 100% YoY
The revenue has plunged by 97% YoY and by 94% from the previous quarter
The company's gross profit has shrunk by 97% YoY and by 94% QoQ
Key stats
What are the main financial stats of PIRS
Market
Valuations
Earnings
Shares outstanding
1.32M
Market cap
$21.04M
Enterprise value
$1.67M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.29
Price to sales (P/S)
15.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.24
Revenue
$1.35M
EBIT
-$15.95M
EBITDA
-$16.21M
Free cash flow
-$25.67M
Per share
Balance sheet
Liquidity
EPS
-$12.1
Free cash flow per share
-$19.45
Book value per share
$12.32
Revenue per share
$1.02
TBVPS
$15.55
Total assets
$20.52M
Total liabilities
$4.25M
Debt
$0
Equity
$16.27M
Working capital
$16.27M
Debt to equity
0
Current ratio
4.82
Quick ratio
4.76
Net debt/EBITDA
1.19
Margins
Efficiency
Dividend
EBITDA margin
-1,198.7%
Gross margin
100%
Net margin
-1,180%
Operating margin
-1,266%
Return on assets
-56.1%
Return on equity
-76.2%
Return on invested capital
-785.8%
Return on capital employed
-98.1%
Return on sales
-1,180%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PIRS stock price
How has the Pieris Pharmaceuticals stock price performed over time
Intraday
-0.47%
1 week
-0.1%
1 month
-5.15%
1 year
-8.21%
YTD
9.44%
QTD
-3.9%
Financial performance
How have Pieris Pharmaceuticals's revenue and profit performed over time
Revenue
$1.35M
Gross profit
$1.35M
Operating income
-$17.12M
Net income
-$15.95M
Gross margin
100%
Net margin
-1,180%
The revenue has plunged by 97% YoY and by 94% from the previous quarter
The company's gross profit has shrunk by 97% YoY and by 94% QoQ
The operating income has soared by 53% YoY and by 34% from the previous quarter
The net income is up by 43% year-on-year and by 33% since the previous quarter
Growth
What is Pieris Pharmaceuticals's growth rate over time
Valuation
What is Pieris Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.29
P/S
15.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.24
The EPS has soared by 57% YoY and by 35% from the previous quarter
PIRS's P/B is 57% below its 5-year quarterly average of 3.0 but 43% above its last 4 quarters average of 0.9
Pieris Pharmaceuticals's equity has decreased by 47% YoY and by 13% QoQ
The revenue has plunged by 97% YoY and by 94% from the previous quarter
Efficiency
How efficient is Pieris Pharmaceuticals business performance
PIRS's return on invested capital has dropped by 74% since the previous quarter
Pieris Pharmaceuticals's ROA has plunged by 62% YoY but it has increased by 10% from the previous quarter
PIRS's return on equity is up by 22% year-on-year and by 22% since the previous quarter
Dividends
What is PIRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PIRS.
Financial health
How did Pieris Pharmaceuticals financials performed over time
Pieris Pharmaceuticals's quick ratio has soared by 199% YoY and by 42% from the previous quarter
PIRS's current ratio has soared by 135% year-on-year and by 22% since the previous quarter
The debt is 100% lower than the equity
PIRS's debt to equity has plunged by 100% YoY
The debt has shrunk by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.